Tivic Health Systems, Inc.
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Tivic Health Systems, Inc. (Nasdaq: TIVC) is a diversified immunotherapeutics company that develops and commercializes bioelectronic and biologic therapies targeting immune system dysregulation; its commercial product is the ClearUP device, a handheld, FDA-cleared bioelectronic sinus pain relief system that delivers microcurrent stimulation to alleviate sinus pain, pressure, congestion, and headaches associated with allergies, colds, flu, and sinusitis; the company advances a pipeline including Entolimod, a late-stage TLR5 agonist biologic for acute radiation syndrome and neutropenia with Fast Track designation, and a patent-pending non-invasive cervical vagus nerve stimulation (ncVNS) device for inflammatory conditions. Founded in 2016 and headquartered in Fremont, California, Tivic operates primarily in the United States with worldwide rights to its key assets and targets consumer, clinical, and government markets in healthcare sectors such as medical devices and biopharmaceuticals. Recent developments include the February 2025 acquisition of exclusive worldwide license rights to Statera's Phase III TLR5 agonist program, encompassing Entolimod and over 60 patents; extension of Entolimod rights to neutropenia in March 2025; entry into a GMP manufacturing validation agreement with Scorpius Biomanufacturing in 2025; completion of the ncVNS optimization study; filing of new patent applications in November 2025 for TLR5 agonists in cancer therapies and optimized ncVNS specifications; securing a BARDA meeting for Entolimod in acute radiation syndrome; raising funds via a preferred equity purchase agreement up to $8.4 million and a $25 million equity line of credit; and plans to exit the ClearUP consumer business by year-end 2025 to focus on high-value therapeutics.
Tivic Health Systems Rebrands as Valion Bio, Reflecting Completed Transformation into a Late-Stage Biopharmaceutical Company with Government-Backed Asset and Potential Multiple Revenue Stream Model
Tivic Health Systems (NASDAQ:TIVC) Director Sheryle Bolton Purchases 10,000 Shares of Stock
Tivic Health Selected to Present Entolimod™ as a Radiation Countermeasure and its Plans for an Oral Transmucosal Program to the Department of War Tech Watch Program on May 7th
Reviewing Omnicell (NASDAQ:OMCL) & Tivic Health Systems (NASDAQ:TIVC)
Tivic Health Systems Touts Entolimod Phase 3 ARS Path, Eyes BLA in 2027-2028 at Conference
Financial Comparison: Tivic Health Systems (NASDAQ:TIVC) versus Rennova Health (OTCMKTS:RNVA)
Tivic Receives Formal Request for Information from Ukrainian Ministry of Health Regarding Strategic Stockpiling of Entolimod
Head to Head Analysis: Tivic Health Systems (NASDAQ:TIVC) versus American Well (NYSE:AMWL)
Tivic CEO To Present at the Upcoming Emerging Growth's April 2026 Virtual Conference
Tivic Secures NIAID Non-Clinical Evaluation Agreement for Entolimod, Targeting Gastrointestinal Acute Radiation Syndrome
Tivic Health Systems, Inc. (TIVC) Q4 2025 Earnings Call Prepared Remarks Transcript
Tivic Reports Full Year 2025 Results
Tivic Health CEO Letter to Shareholders
Reviewing Hims & Hers Health (NYSE:HIMS) & Tivic Health Systems (NASDAQ:TIVC)
Tivic To Report 2025 Year-End Financial Results Via Conference Call and Webcast on March 25th at 1:30pm PT / 4:30pm ET
Biotech Veteran Michael K. Handley Named CEO of Tivic Health Systems to Spearhead Strategic Expansion in Biopharma
Tivic and BARDA Continue Discussions of Entolimod for Acute Radiation Syndrome on March 10
Tivic, BARDA Discuss Entolimod(TM) for Acute Radiation Syndrome at TechWatch Meeting
Tivic to Showcase Strategic Pivot and Forward Outlook on Advancing Entolimod(TM) to Commercialization at DealFlow Discovery Conference
Tivic Health Systems (NASDAQ:TIVC) Trading Up 0.8% – Time to Buy?